Diabetic macular edema is considered the most important factor related to visual impairment in patients with diabetic retinopathy. Together with the use of grid and focal laser photocoagulation, today the intravitreal administration of pharmacotherapies represents the standard of care for the treatment of this complication: anti-vascular endothelium growth factor agents and steroids are the drugs currently used for this aim. Differently from laser therapy, which prevents visual deterioration, the intravitreal approach allows the promotion of visual recovery. However, the intravitreal injections require to be repeated with high frequency, and this carries the risk of drug- and procedure-related adverse effects.

Keywords:
Diabetic macular edema, Intravitreal pharmacotherapies , Steroids, Triamcinolone acetonide, Fluocinolone acetonide, Dexamethasone implant
1.
Aroca PR, Salvat M, Fernandez J, et al: Risk factors for diffuse and focal macular edema. J Diabetes Compl 2004;18:211-215.
2.
Wild S, Roglic G, Green A, et al: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053.
3.
Chen E, Looman M, Laouri M, et al: Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin 2010;26:1587-1597.
4.
Ferris FL III, Patz A: Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol 1984;28(suppl):452-461.
5.
American Academy of Ophthalmology Retina Panel Preferred Practice Pattern Guidelines: Diabetic Retinopathy. San Francisco, American Academy of Ophthalmology, 2010.
6.
Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-1806.
7.
Mitchell P, Bandello F, Schmidt-Erfurth U, et al: The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-625.
8.
Diabetic Retinopathy Clinical Research Network: Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-1077.
9.
Diabetic Retinopathy Clinical Research Network: Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118:609-614.
10.
Bhagat N, Grigorian RA, Tutela A, et al: Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009;54:1-32.
11.
Funatsu H, Yamashita H, Noma H, et al: Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 2002;133:70-77.
12.
Funatsu H, Yamashita H, Ikeda T, et al: Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2003;110:1690-1696.
13.
Nguyen QD, Tatlipinar S, Shah SM, et al: Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006;142:961-969.
14.
Massin P, Bandello F, Garweg JG, et al: Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33:2399-2405.
15.
Nguyen QD, Brown DM, Marcus DM, et al: Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789-801.
16.
Do DV, Nguyen QD, Khwaja AA, et al: Ranibizumab for Edema of the Macula in Diabetes Study: 3-year outcomes and the need for prolonged frequent treatment (READ-2). Arch Ophthalmol 2012;8:1-7.
17.
Elman MJ, Qin H, Aiello LP, et al: Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012;119:2312-2318.
18.
Scott IU, Edwards AR, Beck RW, et al: A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-1867.
19.
Rajendram R, Fraser-Bell S, Kaines A, et al: A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012;130:972-979.
20.
Soheilian M, Ramezani A, Obudi A, et al: Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009;116:1142-1150.
21.
Cunningham ET Jr, Adamis AP, Altaweel M, et al: A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112:1747-1757.
22.
Sultan MB, Zhou D, Loftus J, et al: A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011;118:1107-1118.
23.
Do DV, Nguyen QD, Boyer D, et al: One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012;119:1658-1665.
24.
Summary of Product Characteristics 2011. Basel, Novartis Pharma, 2011.
25.
Nauck M, Roth M, Tamm M, et al: Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is down-regulated by corticosteroids. Am J Respir Cell Mol Biol 1998;16:398-406.
26.
Tamura H, Miyamoto K, Kiryu J, et al: Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005;46:1440-1444.
27.
Penfold P, Gyory J, Hunyor A, et al: Exudative macular degeneration and intravitreal Triamcinolone. A pilot study. Aust NZ J Ophthalmol 1995;23:292-298.
28.
Jonas J, Sofker A: Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001;132:425-427.
29.
Audren F, Erginay A, Haouchine B, et al: Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand 2006;84:624-630.
30.
Massin P, Audren F, Haouchine B, et al: Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004;111:218-224.
31.
Avitabile T, Longo A, Reibaldi A: Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2005;140:695-702.
32.
Jonas JB, Kampperter BA, Harder B, et al: Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 2006;22:200-207.
33.
Sutter FK, Simpson JM, Gillies MC: Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo controlled clinical trial. Ophthalmology 2004;111:2044-2049.
34.
Gillies MC, Sutter FK, Simpson JM, et al: Intravitreal triamcinolone for refractory diabetic macular edema two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113:1533-1538.
35.
Gillies MC, Simpson JM, Gaston C, et al: Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology 2009;116:2182-2187.
36.
Diabetic Retinopathy Clinical Research Network: A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447-1449.
37.
Diabetic Retinopathy Clinical Research Network: Three-year follow-up of a randomized clinical trial comparing focal/grid laser photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127:245-251.
38.
Bressler NM, Edwards AR, Beck RW, et al: Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol 2009;127:1566-1571.
39.
Diabetic Retinopathy Clinical Research Network: Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema following focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina 2011;31:1009-1027.
40.
Jaffe GJ, Martin D, Callanan D, et al: Fluocinolone acetonide implant (Retisert) for non-infectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006;113:1020-1027.
41.
Pearson PA, Comstock TL, Ip M, et al: Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011;118:1580-1587.
42.
Campochiaro PA, Hafiz G, Shah SM, et al: Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010;117:1393-1399.
43.
Campochiaro PA, Brown DM, Pearson A, et al: Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011;118:626-635.
44.
Campochiaro PA, Brown DM, Pearson A, et al: Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012;119:2125-2132.
45.
Lowder C, Belfort R Jr, Lightman S, et al: Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011;129:545-553.
46.
Haller JA, Bandello F, Belfort R Jr, et al: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-1146.
47.
Haller JA, Dugel P, Weinberg DV, et al: Evaluation of safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina 2009;29:46-51.
48.
Kuppermann BD, Blumenkranz MS, Haller JA, et al: Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309-317.
49.
Haller JA, Kuppermann BD, Blumenkranz MS, et al: Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010;128:289-296.
50.
Boyer DS, Faber D, Gupta S, et al: Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011;31:915-923.
51.
Zucchiatti I, Lattanzio R, Querques G, et al: Intravitreal dexamethasone implant in patients with persistent diabetic macular edema. Ophthalmologica 2012;228:117-122.
52.
Pacella E, Vestri AR, Muscella R, et al: Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema. Clin Ophthalmol 2013;7:1423-1428.
53.
Lazic R, Lukic M, Boras I, et al: Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Retina 2014;34:719-724.
54.
Callanan D, Gupta S, Boyer D, et al: Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 2013;120:1843-1851.
55.
Bandello F, Battaglia Parodi M, Tremolada G, et al: Steroids as part of combination treatment: the future for the management of macular edema? Ophthalmologica 2010;224(suppl 1):41-45.
56.
Bandello F, Zarbin MA, Lattanzio R, Zucchiatti I: Clinical Strategies in the Management of Diabetic Retinopathy: A Step-by-Step Guide for Ophthalmologists. Berlin, Springer, 2013.
57.
Stewart MW: Corticosteroid use for diabetic macular edema: old fad or new trend? Curr Diab Rep 2012;12:364-375.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.